MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on December 7, 2006; DOI: 10.1124/mol.106.032086

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.032086v1
71/3/826    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siu, E. C. K.
Right arrow Articles by Tyndale, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siu, E. C. K.
Right arrow Articles by Tyndale, R. F.


Received for publication October 23, 2006.
Revised December 6, 2006.
Accepted for publication December 6, 2006.

Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57Bl/6 mice

Eric C. K. Siu 1 Rachel F. Tyndale 1*

1 Centre for Addiction and Mental Health and University of Toronto

* Address correspondence to: E-mail: r.tyndale{at}utoronto.ca

Abstract

DBA/2 and C57Bl/6 are two commonly used mouse strains that differ in response to nicotine. Previous studies have shown that the nicotine metabolizing enzyme CYP2A5 differs in coumarin metabolism between these two strains suggesting differences in nicotine metabolism. Nicotine was metabolized to cotinine in vitro by two enzymatic sites. The high-affinity sites exhibited similar parameters (Km: 10.7 ± 4.8 vs. 11.4 ± 3.6 µM; Vmax: 0.58 ± 0.18 vs. 0.50 ± 0.07 nmol/min/mg, for DBA/2 and C57Bl/6, respectively). In vivo, the elimination half-lives of nicotine (1 mg/kg, s.c.) were also similar between DBA/2 and C57Bl/6 mice (8.6 ± 0.4 vs. 9.2 ± 1.6 min, respectively); however, cotinine levels were much higher in DBA/2 mice. The production and identity of the putative cotinine metabolite 3'-hydroxycotinine in mice was confirmed by LC/MS/MS. The in vivo half-life of cotinine (1 mg/kg, s.c.) was significantly longer in the DBA/2 mice compared to the C57Bl/6 mice (50.2 ± 4.7 vs. 37.5 ± 9.6 min, respectively, p<0.05). The in vitro metabolism of cotinine to 3'-hydroxycotinine was also less efficient in DBA/2 than C57Bl/6 mice (Km: 51.0 ± 15.6 vs. 9.5 ± 2.1 µM, p<0.05; Vmax: 0.10 ± 0.01 vs. 0.04 ± 0.01 nmol/min/mg, p<0.05, respectively). Inhibitory antibody studies demonstrated that the metabolism of both nicotine and cotinine was mediated by CYP2A5. Genetic differences in Cyp2a5 potentially contributed to similar nicotine but different cotinine metabolism, which may confound interpretation of nicotine pharmacological studies and studies utilizing cotinine as a biomarker.


Key words: Mass Spectroscopy, Cytochrome P450, Genetics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
E. C.K. Siu and R. F. Tyndale
Selegiline Is a Mechanism-Based Inactivator of CYP2A6 Inhibiting Nicotine Metabolism in Humans and Mice
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 992 - 999.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics